BCRX
$7.79-2.87%
BioCryst Pharmaceuticals Inc.Stock · HealthcareRussell 2000 0.07%Nasdaq Composite 0.007%Russell 3000 0.004%US Stock Market 0.004%
BCRX financial statements
The full income statement, balance sheet, and cash-flow statement for BioCryst Pharmaceuticals Inc. (BCRX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 206.9M2024-09 207.1M2024-12 209.0M2025-03 209.3M2025-06 209.9M2025-09 210.5M2025-12 250.8M2026-03 254.2M2026-06 255.5M+23.5% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 875M+94.1% | 451M+36.0% | 331M+22.4% | 271M+72.3% | 157M+782.4% | |
| Cost of revenue | 19.1M+55.5% | 12.3M+173.8% | 4.48M-30.1% | 6.41M-11.4% | 7.23M+366.4% | |
| Research & development | 166M-4.9% | 175M-19.4% | 217M-14.5% | 253M+21.3% | 209M+69.8% | |
| Selling, general & administrative | 349M+30.9% | 266M+24.4% | 214M+34.3% | 159M+34.1% | 119M+74.9% | |
| Operating income | 341M+13508.9% | -2.54M+97.5% | -104M+30.1% | -148M+16.5% | -178M-1.7% | |
| Interest expense | 78.9M-19.9% | 98.5M-9.0% | 108M+9.2% | 99.1M+67.1% | 59.3M+308.9% | |
| Other non-operating income | -73.6M+12.8% | -84.4M+31.1% | -123M-27.7% | -95.9M | — | |
| Pre-tax income | 267M+407.5% | -87.0M+61.6% | -226M+7.4% | -244M-34.4% | -182M+0.5% | |
| Income tax | 3.53M+83.2% | 1.93M+521.6% | 310K-88.7% | 2.73M+21.3% | 2.25M | |
| Net income | 264M+396.9% | -88.9M+60.8% | -227M+8.3% | -247M-34.3% | -184M-0.7% | |
| $1.21+381.4% | -$0.43+63.6% | -$1.18+11.3% | -$1.33-29.1% | -$1.03+5.5% | ||
| EPS (basic) | $1.26+393.0% | -$0.43+63.6% | -$1.18+11.3% | -$1.33-29.1% | -$1.03+5.5% | |
| Weighted-avg shares (basic) | 210M+1.5% | 207M+7.5% | 192M+3.4% | 186M+3.8% | 179M+7.1% | |
| Weighted-avg shares (diluted) | 219M+5.7% | 207M+7.5% | 192M+3.4% | 186M+3.8% | 179M+7.1% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 404M-4.2% | 422M-14.9% | 496M-4.0% | 517M-8.8% | 566M+74.8% | ||
| Cash & equivalents | 89.7M-14.3% | 105M-5.4% | 111M-63.7% | 305M-39.6% | 504M+85.4% | |
| Short-term investments | 185M-14.4% | 216M | — | — | — | |
| Accounts receivable | 107M+35.1% | 79.1M+38.8% | 57.0M+12.6% | 50.6M+72.0% | 29.4M+240.2% | |
| Inventory | 5.40M-33.3% | 8.09M-71.8% | 28.7M+4.2% | 27.5M+74.4% | 15.8M+124.3% | |
| Prepaid expenses | 17.2M+24.9% | 13.8M-29.6% | 19.5M+55.3% | 12.6M+26.0% | 9.99M+80.6% | |
| 514M+4.8% | 490M-5.1% | 517M-6.0% | 550M-6.5% | 588M+75.7% | ||
| Property, plant & equipment | 8.78M+12.9% | 7.78M-1.7% | 7.91M-8.2% | 8.62M-1.1% | 8.71M+22.5% | |
| Operating lease right-of-use | 7.55M-6.4% | 8.06M-7.2% | 8.68M+104.7% | 4.24M-34.5% | 6.47M | |
| Long-term investments | 61.2M+201.0% | 20.3M | 0.00-100.0% | 18.1M+164.7% | 6.83M | |
| Other non-current assets | 5.67M+10.0% | 5.16M+6346.3% | 80.0K-98.8% | 6.81M+5.2% | 6.47M+70.2% | |
| 196M+22.2% | 160M+6.9% | 150M+42.1% | 106M+1.7% | 104M-1.8% | ||
| Accounts payable | 15.8M+35.9% | 11.6M-44.3% | 20.9M+45.5% | 14.4M-48.4% | 27.8M+48.6% | |
| Accrued liabilities | 126M+11.6% | 113M+10.1% | 103M+17.5% | 87.6M+20.5% | 72.7M+114.1% | |
| Deferred revenue | 0.00 | — | 0.00-100.0% | 1.22M-13.9% | 1.42M+847.3% | |
| Current lease liability | 317K-66.2% | 937K-11.4% | 1.06M-30.2% | 1.52M-16.7% | 1.82M+54.3% | |
| Finance lease liability (current) | 1.31M-28.5% | 1.83M+15.4% | 1.59M+86.4% | 853K | — | |
| 633M-34.5% | 966M-0.6% | 972M | — | — | ||
| Long-term debt | 0.00-100.0% | 315M+3.8% | 303M+30.9% | 232M+70.2% | 136M+13.7% | |
| Deferred revenue (non-current) | 0.00 | — | — | — | — | |
| Non-current lease liability | 8.57M+8.2% | 7.92M-5.6% | 8.39M+108.3% | 4.03M-32.5% | 5.96M+54.0% | |
| Operating lease liability (total) | 8.89M+0.3% | 8.86M-6.2% | 9.45M+70.4% | 5.54M-28.8% | 7.78M+54.1% | |
| Finance lease liability (total) | 2.75M-30.5% | 3.96M-10.7% | 4.43M+68.6% | 2.63M | — | |
| Finance lease liability | 1.44M-32.2% | 2.12M-25.3% | 2.85M+60.1% | 1.78M | — | |
| -119M+75.0% | -476M-4.5% | -456M-54.6% | -295M-175.4% | -107M-455.4% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 2.13M+2.2% | 2.08M+1.3% | 2.06M+9.5% | 1.88M+2.0% | 1.84M+4.2% | |
| Additional paid-in capital | 1.38B+7.3% | 1.29B+5.6% | 1.22B+5.5% | 1.16B+5.4% | 1.10B+9.6% | |
| Retained earnings | -1.51B+14.9% | -1.77B-5.3% | -1.68B-15.6% | -1.45B-20.5% | -1.21B-18.0% | |
| Accumulated other comprehensive income | 38.0K-95.9% | 921K-31.1% | 1.34M+5042.3% | 26.0K-85.3% | 177K+5800.0% | |
| Total liabilities & equity | 514M+4.8% | 490M-5.1% | 517M-6.0% | 550M-6.5% | 588M+75.7% | |
| Common shares issued | 213M+2.2% | 209M+1.3% | 206M+9.5% | 188M+1.9% | 184M+4.2% | |
| Common shares outstanding | 213M+2.2% | 209M+1.3% | 206M+9.5% | 188M+1.9% | 184M+4.2% | |
| Shares outstanding (cover) | 251M+20.0% | 209M+1.4% | 206M+9.4% | 188M+2.1% | 185M+4.2% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 347M+767.8% | -52.0M+45.3% | -95.1M+41.2% | -162M-13.9% | -142M-5.2% | ||
| Depreciation & amortization | 1.39M+11.5% | 1.25M-24.7% | 1.66M+15.2% | 1.44M+84.9% | 777K+3.9% | |
| Share-based compensation | 85.1M+30.0% | 65.4M+17.6% | 55.6M+24.4% | 44.7M+29.0% | 34.6M+134.1% | |
| Deferred income taxes | -1.21M-242.4% | -354K+48.1% | -682K-6300.0% | 11.0K+106.9% | -159K | |
| Change in inventory | 1.64M-60.6% | 4.16M+187.2% | 1.45M-88.3% | 12.4M+41.7% | 8.77M+24.5% | |
| Change in payables | 57.8M+291.2% | 14.8M+17.9% | 12.5M+156.0% | -22.4M-156.7% | 39.4M+127.1% | |
| -13.7M-126.0% | 52.6M+140.0% | -131M-2.5% | -128M-911.4% | 15.8M+330.5% | ||
| Capital expenditure | 2.47M+119.6% | 1.12M-48.2% | 2.17M+60.5% | 1.35M-43.4% | 2.38M+364.0% | |
| Free cash flow | 345M+749.0% | -53.1M+45.4% | -97.3M+40.4% | -163M-12.9% | -145M-6.6% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -350M-5974.1% | -5.76M-117.7% | 32.5M-63.1% | 88.0M-75.5% | 360M+19.7% | ||
| Long-term debt issued | 0.00 | 0.00-100.0% | 300M+310.6% | 73.1M | 0.00 | |
| Long-term debt repaid | 300M | 0.00-100.0% | 240M | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 50.0M-46.4% | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 1.27M+235.7% | -936K-358.6% | 362K-36.0% | 566K+697.2% | 71.0K | |
| Net change in cash | -15.0M-144.7% | -6.12M+96.8% | -194M+3.8% | -201M-186.3% | 233M+47.1% | |
| Interest paid | 23.7M-21.9% | 30.4M+37.2% | 22.1M | 0.00-100.0% | 900K | |
| Income taxes paid | 2.80M+74.9% | 1.60M+11.8% | 1.43M-59.5% | 3.54M+2901.7% | 118K | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.96B+24.5% | 1.57B+28.1% | 1.23B-42.7% | 2.14B-16.3% | 2.56B+93.8% | |
| P/E | 7.4× | — | — | — | — | |
| P/S | 2.2×-35.9% | 3.5×-9.8% | 3.9×-57.0% | 9.0×-44.8% | 16.3×-78.0% | |
| P/FCF | 5.7× | — | — | — | — | |
| Earnings yield | 13.5% | — | — | — | — | |
| FCF yield | 17.6% | — | — | — | — | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: BCRX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all BCRX filings on SEC EDGAR → Not investment advice.